NCT06972615招募中2 期
A Phase II, Single Arm Study, Evaluating Intravesical Gemcitabine/Docetaxel in Combination With Systemic Pembrolizumab in Subjects With High Risk NMIBC Unresponsive or Exposed to Bacillus Calmet-Guerin (BCG) Therapy
BLATAM1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2026年5月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- eficacy
研究概览
简要总结
interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC
详细描述
patients will receive intrravesical chemotherapy every 3 weeks and systemic pembrolizumb every 6 week. for a total of 1 year of treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be willing and able to provide documented informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
- •Be ≥18 years of age on the day of signing informed consent.
- •Have a histologically confirmed diagnosis of high-risk non-muscle invasive (T1, High Grade Ta and/or CIS) transitional cell carcinoma of the bladder. Subjects with tumors of mixed transitional/non-transitional cell histology are allowed, but transitional cell carcinoma must be the predominant histology. Subjects with predominant or exclusively non-transitional cell histology are not allowed. Confirmation of histology, grade and stage will be performed by central review and must be completed during the screening period and prior to enrollment.
- •In subjects who have papillary tumors (Ta and T1), a complete TURBT must have been performed, as characterized by:Attainment of a visually complete resection of all papillary tumors (Ta and T1) 5- Have been treated with adequate BCG therapy and have developed high risk NMIBC that is unresponsive or exposed to BCG therapy.
- •Adequate BCG therapy must include:
- •An induction course with at least 5 out of 6 BCG instillations (adequate induction); and
- •At least 7 out of 9 BCG instillations within 9 months of the first instillation of adequate induction therapy
- •BCG unresponsive high risk NMIBC is defined as:
- •Stage progression at 3 months (±4 weeks) despite adequate induction therapy (e.g., Ta to T1, or CIS to T1; note: adequate induction therapy only, defined above, is required in this case); or
- •High grade T1 disease at the first evaluation after adequate BCG induction or
- •Persistent high risk NMIBC at 6 months (±4 weeks) after adequate BCG; or
- •Recurrent high risk NMIBC within 12 months of the last BCG instillation despite having received adequate BCG.
- •BCG Exposed is defined as: having high-grade persistent (BCG resistant) or recurrent NMIBC within 24 months of the last BCG dose but not meeting the definition of BCG-unresponsive
排除标准
- •1. Has muscle-invasive (i.e. T2, T3, T4) locally advanced non-resectable or metastatic urothelial carcinoma.
- •2. Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) non-muscle-invasive transitional cell carcinoma of the urothelium.
- •3. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •4. Has undergone any intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy/ transurethral resection of bladder tumor to starting trial treatment. (Note: A single dose of intravesical treatment given as part of the most recent cystoscopy/ transurethral resection of bladder tumor, during the screening period, such as with chemotherapy as per local/regional practices, is acceptable.)
- •5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Cycle 1, Day 1 or who has not recovered (ie, ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
研究组 & 干预措施
treatment
Experimental
intrravesical docetaxel plus gemcitabine and intravenous pembrolizumab
干预措施: intravesical Chemotherapy docetaxel/gemcitabine (Drug)
结局指标
主要结局
eficacy
时间窗: 3 months
Complete Response rate
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: 1 year
To evaluate safety and tolerability of systemic pembrolizumab in combination with intravesical gemcitabine/docetaxel
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Assessing the safety of atezolizumab being directly administered to the bladder in bladder cancer patients undergoing radical cystectomyrothelial cell carcinoma of the bladderCancerISRCTN15842444Sheffield Teaching Hospitals NHS Foundation Trust56
尚未招募
4 期
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder CancerNon-muscle-invasive Bladder CancerNCT05580354Ruijin Hospital42
招募中
1 期
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialNon-Muscle Invasive Bladder CarcinomaStage 0is Bladder Cancer AJCC v8Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8NCT06704191Mayo Clinic40
已完成
不适用
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary BladderTransitional Carcinoma of Urinary BladderNCT00539773King Faisal Specialist Hospital & Research Center10
招募中
1 期
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2High-risk Non-muscle Invasive Bladder CancerNCT06378242RemeGen Co., Ltd.24